<DOC>
	<DOCNO>NCT00111657</DOCNO>
	<brief_summary>The purpose study determine whether PEG-uricase ( chemically modify recombinant mammalian enzyme degrades uric acid ) effective control hyperuricemia patient chronic gout , tolerate , respond adequately , conventional therapy gout . Funding Source - FDA OOPD</brief_summary>
	<brief_title>Pegylated Recombinant Mammalian Uricase ( PEG-uricase ) Treatment Refractory Gout</brief_title>
	<detailed_description>Inflammatory arthritis patient gout cause crystal monosodium urate ( MSU ) form result chronically elevate level uric acid plasma extracellular fluid . Recurrent attack usually prevent treatment drug block urate synthesis inhibit xanthine oxidase , promote uric acid excretion . If various reason ( noncompliance , drug intolerance , inadequate dosage , inefficacy ) therapy fail maintain serum urate concentration 6 mg/dL , gout progress chronic stage characterize destructive arthropathy , deposition urate crystal soft tissue ( tophus ) , nephropathy . The management chronic gout patient often complicate co-morbidities hypertension , heart disease , diabetes , renal insufficiency , may limit use anti-inflammatory agent treat arthritis . Urate level low gout occur specie express enzyme urate oxidase ( uricase ) , convert urate soluble easily excrete compound allantoin . Humans express enzyme owe mutation uricase gene evolution . Parenteral uricase thus potential mean control hyperuricemia deplete urate store patient chronic , refractory gout . Infusion recombinant fungal uricase effective prevent acute uric acid nephropathy due tumor lysis patient malignancy . However , short circulate life potential immunogenicity fungal uricase prevents chronic use treat gout . PEG-uricase recombinant porcine urate oxidase multiple strand polyethylene glycol ( PEG ) average molecular weight 10,000 attach . `` PEGylation '' intend reduce immunogenicity uricase , greatly prolong circulate life . This `` mammalian '' PEG-uricase non-immunogenic effective prevent uric acid nephropathy uricase-deficient strain mouse ( Kelly et al , J Am Soc Nephrol 12:1001-09 , 2001 ) . It license Savient Pharmaceuticals clinical development , receive Orphan Drug designation treatment refractory gout FDA Office Orphan Product Development . In Phase I trial sponsor Savient Pharmaceuticals 24 subject symptomatic gout , single intravenous ( IV ) infusions 0.5 12 mg PEG-uricase well tolerate , dose 4 mg 12 mg , effective normalizing plasma urinary uric acid level 21-day period post-infusion . Some subject trial develop antibody PEG-uricase , serious adverse event observe attack gout . The present Phase II clinical trial subject refractory gout evaluate efficacy , safety , immunogenicity PEG-uricase administer dose 8 mg IV infusion every 3 week , total 5 infusion . The primary measure efficacy reduction plasma uric acid le 6 mg/dL , reduction ratio uric acid creatinine urine &lt; 0.2 . In addition , ability PEG-uricase low total uric acid pool size evaluate subset treatment subject . Uric acid pool size measure method involves infusion uric acid label N15 , stable ( non-radioactive ) isotope nitrogen .</detailed_description>
	<mesh_term>Gout</mesh_term>
	<criteria>Age &gt; 18 year Symptomatic gout Serum uric acid &gt; 7 mg/dL Intolerance , inadequate response , conventional therapy gout Women childbearing potential must negative serum pregnancy test must use approved birth control method End stage renal failure require dialysis Concurrent use uricacid lower agent Glucose6phosphate dehydrogenase ( G6PD ) deficiency A history anaphylactic reaction recombinant protein Concurrent use immunosuppressive therapy ( except need prevention rejection transplant organ , prednisone 10 mg day less treatment gout flare ) A medical psychological condition , opinion investigator , might create undue risk subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Gout</keyword>
	<keyword>Tophi</keyword>
	<keyword>Tophaceous gout</keyword>
	<keyword>Allergy allopurinol</keyword>
	<keyword>Post-transplant gout</keyword>
</DOC>